StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock.
LadRx Stock Performance
LadRx has a 12-month low of $0.05 and a 12-month high of $0.86. The stock's 50 day moving average is $0.09 and its 200-day moving average is $0.12.
Get
LadRx alerts:
LadRx Company Profile
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
See Also
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock.
證券新聞網開始對股票的報導 LaDrX (納斯達克:賽爾特 — 獲得評分) 在星期二早上發表的報告中。該經紀公司對股票發出了持有評級。
LadRx Stock Performance
LadRx has a 12-month low of $0.05 and a 12-month high of $0.86. The stock's 50 day moving average is $0.09 and its 200-day moving average is $0.12.
LADRX 擁有 12 個月的低點 0.05 美元和 12 個月的最高點為 0.86 美元。該股票的 50 日移動平均線為 0.09 美元，而其 200 天移動平均線為 0.12 美元。
Get
LadRx
alerts:
LadRx Company Profile
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.
LADRX Corp. 是一家生物製藥研發公司，致力於新型抗癌候選藥物的發現、研究和臨床開發。它專注於開發 Linker 活性藥物釋放（LADR）技術平台，該平台是一種發現引擎，可幫助創建一系列抗癌分子，避免無法接受的全身毒性，同時將高效藥物直接輸送到腫瘤中。
See Also
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 獲取有關 LADRX 研究報告的免費副本
- 市場節拍週的回顧 — 1/23-1/27
- 為什麼清醒在一天內飆升近 100％
- 乘坐這些鐵路股票以獲得增長和收入
- ASML 今年看到籌碼需求上升，提高了銷售觀點
- KLA 公司：陷入困境的半市場中的實力
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
接收有關 LaDrX 每日的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收對 LADRX 及相關公司的最新新聞和分析師評級的簡要每日摘要。
